Media Coverage
Back to Media CoverageCandidate Cell Therapy Controls Bleeding in Mouse Model of Hemophilia A
Sigilon Therapeutics’ candidate cell therapy for hemophilia A, called SIG-001, delivers sustained production of factor VIII for over six months and corrects bleeding in a hemophilia A mouse model.